Hard gelatin capsules.
Active ingredient: Umifenovir 100 mg.
Inactive ingredients: potato starch 30.14 mg, microcrystalline cellulose 55.76 mg, fumed silica 2.0 mg, povidone K 25 10.1 mg and calcium stearate 2.0 mg.
Administration and dosage
To be administered orally, before meal.
For children aged 6-12 a single dose is 100 mg (1 capsule).
For adults and children from 12 years a single dose is 200 mg (2 capsules).
Reccomendations for the treatment of ARVI and influenza: take one single dose 4 times a day (every 6 hours) for 5 days in a row.
For adults a treatment course may take 4 boxes of 10 pills x 100mg.
Hypersensitivity to umifenovir and other components of the drug, children under 6 years, pregnancy, lactation.
No significant drug interactions were registered.
Store at a temperature not higher than 25 °C.
Keep out of the reach of children.
Arbidol is a broad-spectrum antiviral drug used in the treatment of influenza A and B infections (including swine and avian) and other ARVI and rotavirus pathogens. The drug inhibits fusion between the viral capsid and the cell membrane of the target cell. This prevents viral entry to the target cell, and therefore protects it from infection.
Arbidol was developed in the USSR by a team of scientists from All-Union Scientific Research Chemical-Pharmaceutical Institute, Institute of Medical Radiology of USSR Academy of Medical Sciences and Leningrad Bacteriological and Diagnostic Institute. The international nonproprietary name is Umifenovir. The tests conducted in the USSR and later in Russia showed that the drug has significant antiviaral effects; for instance, in a direct comparison with Tamiflu, Arbidol was shown to achieve a similar efficiency both in vitro and in a clinical setting.
Arbidol reduces the severity of influenza and ARVI and minimizes the incidence of complications. Prophylactic administration significantly reduces the risk of infection in case of contact with a patient with influenza or ARVI. Arbidol exhibits modulatory effects on the immune system. The drug stimulates a humoral immune response (the growth of T-cells, T-helpers and NK cells), induces interferon-production, and stimulates the phagocytic function of macrophages. The drug has also been investigated as a candidate drug for the treatment of hepatitis C.
Arbidol is a low-toxic drug. It is quickly absorbed and distributed to the organs and tissues of the body. Then, it is metabolized in the liver.
- Liu et al (2013) Antiviral and anti-inflammatory activity of arbidol hydrochloride in influenza A (H1N1) virus infection https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003028/
- Leneva et al (2014) Umifenovir (Arbidol) efficacy in experimental mixed viral and bacterial pneumonia of mice https://www.ncbi.nlm.nih.gov/pubmed/25975111
- Kiselev et al (2015) Clinical efficacy of arbidol (umifenovir) in the therapy of influenza in adults: preliminary results of the multicenter double-blind randomized placebo-controlled study ARBITR https://www.ncbi.nlm.nih.gov/pubmed/25823275
- Leneva et al (2016) Virus susceptibility and clinical effectiveness of anti-influenza drugs during the 2010-2011 influenza season in Russia https://www.ncbi.nlm.nih.gov/pubmed/26775570
- Popov et al (2017) Time course of changes in cytokines (IFN-γ, IFN-α, IL-18, TNF-α) in the treatment of moderate influenza A (H1N1) pdm09 (2013-2016) with oseltamivir (Tamiflu) and umifenovir (Arbidol) alone and in combination with Kagocel https://www.ncbi.nlm.nih.gov/pubmed/29171473
- Bulgakova et al (2017) Pharmacoepidemiological study of the course of influenza and other acute respiratory viral infections in risk groups https://www.ncbi.nlm.nih.gov/pubmed/28252630
- Zhang et al (2017) Umifenovir effectively inhibits IL-10 dependent persistent Coxsackie B4 virus infection https://www.ncbi.nlm.nih.gov/pubmed/28263801
- Fink et al (2018) The Antiviral Drug Arbidol Inhibits Zika Virus https://www.ncbi.nlm.nih.gov/pubmed/29895962
- Haviernik et al (2018) Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses https://www.ncbi.nlm.nih.gov/pubmed/29642580
- Pshenichnaya et al (2019) Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR) https://www.ncbi.nlm.nih.gov/pubmed/31094461
- Leneva et al (2019) Umifenovir susceptibility monitoring and characterization of influenza viruses isolated during ARBITR clinical study https://www.ncbi.nlm.nih.gov/pubmed/30431664